first dosage of semaglutide Dosing What was everyone's starting dose,

Updated February 2026 Retatrutide Half-Life and Pharmacokinetics Retatrutide has a ~6-day half-life achieved through fatty acid albumin binding comparable to semaglutide (~7 days) and tirzepatide (~5 days)

The Basics at a Glance Generic name: Retatrutide (development code: LY3437943) Manufacturer: Eli Lilly and Company Drug class: Triple agonist (GLP-1/GIP/glucagon receptor agonist) Administration: Once-weekly subcutaneous injection Dosing range: 2mg to 12mg weekly (gradual titration over 12+ weeks) Half-life: Approximately 6 days (reaches steady state in 45 weeks) FDA status: Phase 3 clinical trials (TRIUMPH program) Expected approval: 20272028 How Retatrutide Differs from Other GLP-1 Medications To understand retatrutide, it helps to see where it fits in the evolution of GLP-1 class medications

If temperatures fall outside of the preset range, the remote monitoring system sends alerts via email, phone call, text or push notification so staff can quickly address issues before they compromise Semaglutide storage temperature

A1C levels typically rise as insulin secretion decreases and glucagon suppression is lost